Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles.
PAD
VCD
bortezomib
fibroblast growth factor receptor 3
gene expression
machine learning
multiple myeloma
treatment response
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
01
2021
accepted:
19
03
2021
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
4
5
2021
Statut:
epublish
Résumé
Multiple myeloma (MM) affects ~500,000 people and results in ~100,000 deaths annually, being currently considered treatable but incurable. There are several MM chemotherapy treatment regimens, among which eleven include bortezomib, a proteasome-targeted drug. MM patients respond differently to bortezomib, and new prognostic biomarkers are needed to personalize treatments. However, there is a shortage of clinically annotated MM molecular data that could be used to establish novel molecular diagnostics. We report new RNA sequencing profiles for 53 MM patients annotated with responses on two similar chemotherapy regimens: bortezomib, doxorubicin, dexamethasone (PAD), and bortezomib, cyclophosphamide, dexamethasone (VCD), or with responses to their combinations. Fourteen patients received both PAD and VCD; six received only PAD, and 33 received only VCD. We compared profiles for the good and poor responders and found five genes commonly regulated here and in the previous datasets for other bortezomib regimens (all upregulated in the good responders):
Identifiants
pubmed: 33937058
doi: 10.3389/fonc.2021.652063
pmc: PMC8083158
doi:
Types de publication
Journal Article
Langues
eng
Pagination
652063Subventions
Organisme : NCI NIH HHS
ID : P30 CA016042
Pays : United States
Informations de copyright
Copyright © 2021 Borisov, Sergeeva, Suntsova, Raevskiy, Gaifullin, Mendeleeva, Gudkov, Nareiko, Garazha, Tkachev, Li, Sorokin, Surin and Buzdin.
Déclaration de conflit d'intérêts
The AG, VT and MS were employed by Omicsway Corp. and Oncobox Ltd. AB was employed by Omicsway Corp. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Genet. 2019 Jan 15;9:717
pubmed: 30697229
Blood. 2011 Jun 9;117(23):6202-13
pubmed: 21474670
Int J Mol Sci. 2020 Jan 22;21(3):
pubmed: 31979006
Leukemia. 2009 Jul;23(7):1337-41
pubmed: 19225538
J Clin Oncol. 2008 Oct 10;26(29):4798-805
pubmed: 18591550
Nat Rev Clin Oncol. 2009 Nov;6(11):638-47
pubmed: 19786984
Cancer Sci. 2019 Oct;110(10):3267-3274
pubmed: 31444836
J Bioinform Comput Biol. 2018 Jun;16(3):1840014
pubmed: 29945499
Annu Int Conf IEEE Eng Med Biol Soc. 2016 Aug;2016:3314-3320
pubmed: 28269014
BMC Med Genomics. 2020 Apr 3;13(Suppl 5):41
pubmed: 32241264
J Natl Compr Canc Netw. 2013 Jan 1;11(1):11-7
pubmed: 23307977
Expert Rev Anticancer Ther. 2020 Dec;20(12):1021-1035
pubmed: 32969752
Blood. 2011 Feb 24;117(8):2396-404
pubmed: 21163924
Leukemia. 2008 Jul;22(7):1419-27
pubmed: 18432260
Clin Cancer Res. 2018 Nov 1;24(21):5292-5304
pubmed: 30037817
BMC Genomics. 2018 Aug 13;19(Suppl 6):565
pubmed: 30367576
J Clin Oncol. 2015 Nov 20;33(33):3921-9
pubmed: 26056177
Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):e545-e550
pubmed: 31262667
N Engl J Med. 2018 Feb 8;378(6):518-528
pubmed: 29231133
Comput Biol Med. 2019 Apr;107:302-322
pubmed: 30771879
Vnitr Lek. 2013 Jul;59(7):627-30
pubmed: 23909272
Blood. 2011 Nov 24;118(22):5752-8; quiz 5982
pubmed: 21849487
Front Oncol. 2019 Jan 04;8:658
pubmed: 30662873
Lancet. 2016 Oct 8;388(10053):1545-1602
pubmed: 27733282
Mol Oncol. 2019 Apr;13(4):909-927
pubmed: 30648789
J Pharm Pharmacol. 2013 Feb;65(2):157-70
pubmed: 23278683
Blood. 2010 Jan 7;115(1):61-70
pubmed: 19837979
Leukemia. 2007 Apr;21(4):838-42
pubmed: 17268529
Blood Cancer J. 2018 Dec 21;9(1):1
pubmed: 30602759
Neuroradiology. 2018 Jul;60(7):693-702
pubmed: 29777252
Blood. 2008 Nov 15;112(10):4235-46
pubmed: 18337559
Br J Haematol. 2007 Jul;138(2):176-85
pubmed: 17593024
Springerplus. 2015 Oct 22;4:635
pubmed: 26543769
BMC Med Genomics. 2020 Sep 18;13(Suppl 8):111
pubmed: 32948183
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Blood. 2010 Oct 7;116(14):2543-53
pubmed: 20574050
Genome Biol. 2014;15(12):550
pubmed: 25516281
Hosp Pharm. 2017 Jan;52(1):27-32
pubmed: 28179738
Nat Commun. 2018 Jul 27;9(1):2943
pubmed: 30054467
Expert Rev Proteomics. 2009 Dec;6(6):675-89
pubmed: 19929612
Br J Haematol. 2019 May;185(3):492-502
pubmed: 30828799
Oncotarget. 2014 Oct 30;5(20):10198-205
pubmed: 25415353
Blood. 2007 Feb 15;109(4):1692-700
pubmed: 17023574
Anticancer Res. 2011 Jan;31(1):113-22
pubmed: 21273588
Cancer Metastasis Rev. 2017 Mar;36(1):179-190
pubmed: 27873079
Leukemia. 2014 Nov;28(11):2229-34
pubmed: 24732597
Leuk Res. 2013 Dec;37(12):1648-55
pubmed: 24210217
Am J Hematol. 2013 Jun;88(6):463-71
pubmed: 23456977
BMC Cancer. 2018 Jul 6;18(1):724
pubmed: 29980194
Leukemia. 2015 Aug;29(8):1713-20
pubmed: 25753926
Clin Cancer Res. 2009 Jan 15;15(2):520-31
pubmed: 19147757
Bioinformatics. 2011 Jul 15;27(14):1986-94
pubmed: 21576180
Blood. 2006 Sep 15;108(6):2020-8
pubmed: 16728703
Oncol Lett. 2019 Sep;18(3):2853-2860
pubmed: 31452764
BMC Bioinformatics. 2019 Jul 25;20(1):405
pubmed: 31345161
Blood. 2020 Aug 20;136(8):936-945
pubmed: 32325490
Leuk Lymphoma. 2012 Sep;53(9):1728-34
pubmed: 22329352
Lancet. 2019 Jul 6;394(10192):29-38
pubmed: 31171419
Nucleic Acids Res. 2017 Jan 4;45(D1):D619-D625
pubmed: 27799471
Blood Rev. 2021 Mar;46:100757
pubmed: 32972803
Sci Rep. 2018 Aug 27;8(1):12922
pubmed: 30150751
BMC Med Genomics. 2015 Dec 30;8:85
pubmed: 26714877
BMC Bioinformatics. 2016 Dec 23;17(Suppl 17):476
pubmed: 28155641
Hematology Am Soc Hematol Educ Program. 2004;:237-56
pubmed: 15561686
Cancers (Basel). 2020 Sep 07;12(9):
pubmed: 32906684
Lancet. 2009 Jul 25;374(9686):324-39
pubmed: 19541364
Proteomics. 2004 Aug;4(8):2320-32
pubmed: 15274126
J Clin Oncol. 2012 Aug 20;30(24):2946-55
pubmed: 22802322
Oncotarget. 2016 Mar 1;7(9):9666-79
pubmed: 26575327
Commun Biol. 2019 Mar 4;2:89
pubmed: 30854481
Int J Hematol. 2013 Mar;97(3):313-23
pubmed: 23456262
Front Oncol. 2020 Feb 18;10:162
pubmed: 32133296
Gastric Cancer. 2016 Apr;19(2):361-369
pubmed: 25678126
Lancet. 2016 Oct 8;388(10053):1459-1544
pubmed: 27733281
Bioinformatics. 2017 Sep 15;33(18):2938-2940
pubmed: 28645171
Semin Cancer Biol. 2020 Feb;60:311-323
pubmed: 31412295
Nat Commun. 2016 Jul 01;7:12050
pubmed: 27363682
Sci Data. 2019 Apr 23;6(1):36
pubmed: 31015567
Blood. 2007 Apr 15;109(8):3177-88
pubmed: 17185464
Lancet. 2017 Feb 4;389(10068):519-527
pubmed: 28017406
Leukemia. 2006 Jul;20(7):1288-90
pubmed: 16688228
Br J Haematol. 2008 Mar;140(6):625-34
pubmed: 18302711
Exp Hematol Oncol. 2017 May 26;6:16
pubmed: 28560070
Anticancer Res. 2009 Jan;29(1):1-9
pubmed: 19331127
J Cell Biochem. 2020 Aug;121(8-9):3804-3813
pubmed: 31674080
Int J Oncol. 2019 Jan;54(1):370-380
pubmed: 30431083
Anticancer Res. 2010 Jun;30(6):1921-30
pubmed: 20651335
Scand J Clin Lab Invest Suppl. 1997;227:46-63
pubmed: 9127468
Nat Commun. 2018 Sep 13;9(1):3707
pubmed: 30213928
Blood Cancer J. 2014 Jan 17;4:e175
pubmed: 24442204
Blood. 2012 May 10;119(19):4375-82
pubmed: 22422823
BMC Syst Biol. 2017 Oct 3;11(Suppl 5):94
pubmed: 28984192
Leukemia. 2016 Feb;30(2):423-30
pubmed: 26526987
Blood. 2010 May 27;115(21):4168-73
pubmed: 20124509
Front Oncol. 2019 Jul 17;9:658
pubmed: 31380288